tl;dr The FDA will review on priority if the clinical trial (details here -> https://clinicaltrials.gov/ct2/show/NCT03866174 https://clinicaltrials.gov/ct2/sho

tl;dr The FDA will review on priority if the clinical trial (details here -> https://clinicaltrials.gov/ct2/show/NCT03866174 https://clinicaltrials.gov/ct2/show/NCT03866174) succeeds. For people outside of the US (like me) who don't know what "Breakthrough Therapy" is : "Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. he FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases" [1] [1]https://en.wikipedia.org/wiki/Breakthrough_therapy https://en.wikipedia.org/wiki/Breakthrough_therapy